Sorrento Therapeutics Inc...

AI Score

0

Unlock

0.00
-0.00 (-100.00%)
At close: Mar 03, 2025, 3:53 PM
0.00
-57.14%
Pre-market: Jan 02, 2025, 09:30 AM EST
No 1D chart data available
Bid n/a
Market Cap 385.9K
Revenue (ttm) 82.62M
Net Income (ttm) -753.13M
EPS (ttm) -1.1
PE Ratio (ttm) n/a
Forward PE n/a
Analyst n/a
Ask n/a
Volume 21,863
Avg. Volume (20D) 238,409
Open 0.00
Previous Close 0.00
Day's Range 0.00 - 0.00
52-Week Range 0.00 - 0.08
Beta 1.68

About SRNE

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 19, 2007
Employees 949
Stock Exchange NASDAQ
Ticker Symbol SRNE
Full Company Profile